热休克蛋白(HSP70、HSP27)在食管癌组织中表达的意义

目的 :探讨HSP70和HSP2 7在食管癌组织中的表达情况。方法 :采用SP免疫组织化学染色检测 5 9例食管癌组织中HSP70和HSP2 7。结果 :HSP70和HSP2 7的总阳性率分别为 6 4.4 1% (38/5 9)和 5 8.6 2 % (34/5 8) ,HSP70和HSP2 7的共同阳性率为 30 .0 0 % (9/30 )。结论 :在食管癌中HSP70和HSP2 7普遍表达。     

The influence of fear appeals,message design,and masculinity on men's motivation to perform the testicular self‐exam

Despite the significant threat men face for contracting testicular cancer, most men remain completely unaware of this risk. Moreover, men are not regularly performing the testicular self‐exam (TSE) in order to detect this form of cancer in their bodies. The current study attempted to assess whether fear appeals targeted at men will motivate them to begin regular performance of the TSE. Additionally, the influence of message design and masculinity was also tested. Results indicate messages that follow the direction of Witte's (1992, 1994) Extended Parallel Process Model and promote both high threat and high efficacy are successful in increasing men's intentions to perform the TSE. Implications of these findings are discussed.     

羽毛根中MDV抗原和抗体的检测

HVT注苗鸡和未注苗鸡．分别以AIDV强毒接种感染和同居感染,用琼脂扩散试验（AGPT）检测各鸡群不同时期羽囊MDV抗原和抗体。结果显示,HVT苗可使实验鸡羽囊中MDV抗原检出时间推迟,阳性检出率显著降低：而羽囊中MDV抗体检出情况与此正好相反,检出时间早,阳性率高。     

专利视阈下产业技术创新合作网络演化分析——以肿瘤疫苗为例

[目的/意义]旨在研究肿瘤疫苗领域技术创新合作网络演化特征,为我国肿瘤疫苗领域的技术突破和产业发展提供思路。[方法/过程]提出一种产业技术创新合作网络演化特征分析方法和框架。首先引入专利指标法,通过技术生长率、技术成熟系数、技术衰老系数和新技术特征系数等指数的定量计算对肿瘤疫苗产业技术生命周期进行划分;其次利用社会网络分析法构建技术生命周期各阶段合作网络,从节点数、网络密度、中心势、核心-边缘分析等维度对合作网络的拓扑结构演化规律进行分析;从中心度、凝聚子群分析、创新机构等维度对核心个体演化规律进行分析,进而揭示肿瘤疫苗产业技术创新合作网络的动态演化特征。[结果/结论]以肿瘤疫苗战略性新兴产业为案例进行研究,验证方法的有效性和可行性,为肿瘤疫苗领域技术发展战略和技术合作提供理论依据。     

FolFox4与Xelox一线治疗晚期大肠癌分析

目的探讨FolFox4与XElox方案一线治疗晚期大肠癌的临床疗效及不良反应。方法将晚期大肠癌患者64例随机分为两组：FolFox4组采用L—OHP85mg／m2,CF200mg／m2,5-FU1000mg／m2,2周重复1次,28d为一周期;XElox组采用L—OHP130mg／m2、每2周1次,Xeloda1800mg／（m2·d）,21d为一周期。两组都化疗164周期,记录疗效与治疗期间毒副反应。结果FolFox4组总有效率56．3％（18／32）,中位缓解期7．5月,中位生存期11月;Xelox组总有效率46．9％（15／32）,中位缓解期、中位生存期分别为7．0月、9．5月。两组在客观疗效以及中位缓解期、中位生存期方面均无显著性差异。结论FolFox4与XElox方案一线疗效晚期大肠癌客观疗效中位缓解期及中位生存期比较无显著性差异,两组毒副反应均较轻,作为一线治疗晚期大肠癌两方案均可作为首选方案,     

术后康复运动对分化型肺癌内分泌系统调节影响

目的:探讨术后康复运动对分化型肺癌内分泌系统调节影响。方法:以107例进行过肺癌手术的患者为受试对象,随机将患者分为4组,分别进行慢走,康复太极拳,瑜伽,康复体操等4种不同的康复运动,进行为期8周的康复测试,比较不同术后康复运动对分化型肺癌的康复治疗作用,分析了TSH对肺癌康复治疗效果,采用垂体激素的刺激和康复指数作为判定基准,评价不同康复运动的效果。结果:进行慢走,康复太极拳,瑜伽三种康复运动后,患者的康复指数均随运动周数增加,呈现不同程度的递增趋势,而进行康复健美操运动后,康复指数无明显变化。结论:慢走、康复太极拳、瑜伽三种康复运动对垂体激素调节效果明显,对肺癌康复有积极促进作用。     

新福菌素联合卡铂、依托泊苷治疗老年非小细胞肺癌临床疗效观察

目的：评价国产新福菌素对老年非小细胞肺癌（NSCLC）的疗效和不良反应。方法：选取老年NSCLC病例81例，随机分治疗组43例给予新福菌素6μg／kg（第1～4d）。卡铂（CBP）300mg／m^2（第1d），依托泊苷（VP-16）100mg（第1～4或5d）静脉滴注；对照组38例单纯使用CBP和VP—16，剂量和方法同治疗组。21～28d为一个疗程．2～3个疗程评价疗效，随访缓解期和生存期。结果：治疗组有效率为53．49％，对照组有效率为31.58％，差异有显著性（P〈0．05）；中位缓解期分别为6和4．5个月，中位生存期分别为9和7个月．一年生存率分别为39．53％（17／43）和26．32％（10／38）。结论：新福菌素联合CBP、VP—16治疗老年NSCLC有较好的临床疗效及应用价值。     

晚期癌症病人的临终护理

如何提高晚期癌症病人的生活质量,笔者自2003年4月～2005年4月共收晚期癌症病人72例,从72例临终病人的护理过程中,笔者认为:尽量满足临终病人的心理需要;帮助患者创造优美舒适的环境;协助患者减轻躯体和心理的痛苦;做好家属的护理工作等四个方面是让临终病人宁静、舒适地度过余生行之有效的护理方法。     

超声联合双光扫描对乳腺癌诊断价值的评价

目的：评价超声联合双光扫描检查对乳腺癌诊断价值;方法：将术前经超声联合双光扫描诊断的乳腺癌与术后病理对照分析;结果：超声对乳腺癌诊断的准确率为81．25％,双光扫描为68．75％。两者联合的准确率为93．75％;结论：超声联合双光扫描可以提高对乳腺癌的诊断率,两者联合可将乳腺癌的误诊率进一步降低。     

Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up

Objective: In the present study, we have examined the safety and efficacy of recombinant adenovirus encoding human p53 tumor suppressor gene (rAd-p53) injection in patients with advanced non-small-cell lung cancer (NSCLC) in the combination with the therapy of bronchial arterial infusion (BAI). Methods: A total of 58 patients with advanced NSCLC were enrolled in a non-randomized, two-armed clinical trial. Of which, 19 received a combination treatment of BAI and rAd-p53 (the combo group), while the remaining 39 were treated with only BAI (the control group). Patients were followed up for 12 months, with safety and local response evaluated by the National Cancer Institute's Common Toxicity Criteria and response evaluation criteria in solid tumor (RECIST), respectively. Time to progression (TTP) and survival rates were also analyzed by Kaplan-Meier method. Results: In the combo group,19 patients received a total of 49 injections of rAd-p53 and 46 times of BAI, respectively, while 39 patients in the control group received a total of 113 times of BAI. The combination treatment was found to have less adverse events such as anorexia, nausea and emesis, pain, and leucopenia (P<0.05) but more arthralgia. fever, influenza-like symptom, and myalgia (P<0.05), compared with the control group. The overall response rates (complete response (CR)+partial response (PR)) were 47.3% and 38.4% for the combo group and the control group, respectively (P>0.05). Patients in the combo group had a longer TTP than those in the control group (a median 7.75 vs 5.5 months, P=0.018). However, the combination treatment did not lead to better survival, with survival rates at 3, 6, and 12 months in the combo group being 94.74%, 89.47%, and 52.63%, respectively, com-pared with 92.31%, 69.23%, and 38.83% in the control group (P=0.224). Conclusion: Our results show that the combination of rAd-p53 and BAI was well tolerated in patients with NSCLC and may have improved the quality of life and delayed the disease progression. A further study to better determine the efficacy of this combination therapy is warranted.